Eisai currently works across Europe in the areas of Alzheimer’s disease, gastro-intestinal disorders, epilepsy, cervical dystonia and severe, chronic pain, and is moving into neurology, cancer and critical care with its development portfolio.

Development Pipeline

Eisai currently has several compounds undergoing large clinical studies at Phase II and III. One of these is a potential new treatment for painful diabetic neuropathy, post-herpetic neuralgia and epilepsy and was discovered by Eisai London Laboratories at UCL. The success of this drug, together with Eisai’s existing portfolio in this field, will strengthen our position as a leader in the treatment of epilepsy.

There are several oncology compounds in development, from both Eisai’s own discovery laboratories and those of recently acquired affiliates, whose area of expertise is the development of monoclonal antibodies. In the area of critical care, we are targeting the treatment of sepsis and, also, have Phase II trials underway in atherothrombosis and acute coronary syndrome.

For further information on Eisai’s Development Pipeline, click here to access Eisai’s global site

Understanding the future information for investors